Maegim한국어

유틸렉스

263050KOSDAQSector: Pharma & Biotech
₩959 0.00%Market cap ₩35.3BAs of Jul 21, 2026 close · updated once daily
D
Grade D30.4 ptsTop 85% of 2,523 stocks
Financial strength
11.1
Growth momentum
73.3
Price attractiveness
21.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

11.1
How much debt does it carry relative to equity?
Debt-to-equity ratio
161.0%
Below median · Top 87.6% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
44.0%
Below median · Top 94.5% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-183.8%
Below median · Top 79.2% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-156.6%
Below median · Top 94.5% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

73.3
How much did revenue grow in a year?
Revenue growth (YoY)
8.1%
Above median · Top 44.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
262.8%
Above median · Top 1.4% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
28.6%
Above median · Top 30.6% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
48.5%
Above median · Top 30.9% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

21.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 94.5% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
2.31x
Below median · Top 62% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15